Search results
Showing 331 to 345 of 530 results for physical activity
Novii Wireless Patch System for maternal and fetal monitoring (MIB228)
NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring .
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)
Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.
Biographies for all current members of the diagnostics advisory committee.
Depression in children and young people: identification and management (NG134)
This guideline covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression.
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Capecitabine for the treatment of advanced gastric cancer (TA191)
Evidence-based recommendations on capecitabine for treating advanced gastric cancer in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Borderline personality disorder: recognition and management (CG78)
This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.
Antimicrobial stewardship: changing risk-related behaviours in the general population (NG63)
This guideline covers making people aware of how to correctly use antimicrobial medicines (including antibiotics) and the dangers associated with their overuse and misuse. It also includes measures to prevent and control infection that can stop people needing antimicrobials or spreading infection to others. It aims to change people’s behaviour to reduce antimicrobial resistance and the spread of resistant microbes.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.